Develop Chimeric T-cells as therapeutics to ameliorate fibrosis and potentiate recovery of the failing heart.
WP1, we will define the optimal timing of FAP CART treatment. WP2 will leverage technologic innovations to improve the safety of FAP cell depletion. WP3 will focus on identifying new fibroblast targets to ameliorate fibrosis. Right, picorsirius red staining showing efficacy of FAP CART cells. Adapted from [Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature vol. 573 430–433 (2019)].
![WP1, we will define the optimal timing of FAP CART treatment. WP2 will leverage technologic innovations to improve the safety of FAP cell depletion. WP3 will focus on identifying new fibroblast targets to ameliorate fibrosis. Right, picorsirius red staining showing efficacy of FAP CART cells. Adapted from [Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature vol. 573 430–433 (2019)].](https://immunofibhf.wustl.edu/files/2021/10/therapeutic-initiative-figure.png)